WHITEHAWK THERAPEUTICS, INC. Net Change in Cash
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Net Change in Cash of $47.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- WHITEHAWK THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$2.78M, a 101.40% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $198.84M.
- WHITEHAWK THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$9.11M.
- WHITEHAWK THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$4.97M.
- WHITEHAWK THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $8.83M.
- WHITEHAWK THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$34.22M, a 243.36% decline from fiscal 2023.
- WHITEHAWK THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $23.87M.
- WHITEHAWK THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$109.91M, a 176.04% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $47.67M 10-Q · filed 2026-08-06 | |||||||
| 2026-03-31 | -$2.78M 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | $8.83M 10-K · filed 2026-03-12 | |||||||
| 2025-09-30 | $9.20M 10-Q · filed 2025-11-06 | |||||||
| 2025-06-30 | $116.20M 10-Q · filed 2026-08-06 | |||||||
| 2025-03-31 | $198.84M 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | -$34.22M 10-K · filed 2026-03-12 | |||||||
| 2024-09-30 | -$32.35M 10-Q · filed 2025-11-06 | |||||||
| 2024-06-30 | -$21.75M 10-Q · filed 2025-08-07 | |||||||
| 2024-03-31 | -$9.11M 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | $23.87M 10-K · filed 2025-03-28 | |||||||
| 2023-09-30 | $29.78M 10-Q · filed 2024-11-06 | |||||||
| 2023-06-30 | $29.14M 10-Q · filed 2024-08-07 | |||||||
| 2023-03-31 | -$4.97M 10-Q · filed 2024-05-08 | |||||||
| 2022-12-31 | -$109.91M 10-K · filed 2024-03-13 | |||||||
| 2022-09-30 | -$14.11M 10-Q · filed 2023-11-08 | |||||||
| 2022-06-30 | -$30.19M 10-Q · filed 2023-08-09 | |||||||
| 2022-03-31 | -$19.14M 10-Q · filed 2023-05-10 | |||||||
| 2021-12-31 | $144.53M 10-K · filed 2023-03-29 | |||||||
| 2021-09-30 | $156.92M 10-Q · filed 2022-11-09 | |||||||
| 2021-06-30 | $7.22M 10-Q · filed 2022-08-10 | -$5.79M 10-Q · filed 2021-08-11 | ||||||
| 2021-03-31 | $10.56M 10-Q · filed 2022-05-12 | -$3.60M 10-Q · filed 2021-05-17 | ||||||
| 2020-12-31 | -$11.51M 10-K · filed 2022-03-17 | $4.08M 10-K · filed 2021-03-11 | ||||||
| 2020-09-30 | -$8.23M 10-Q · filed 2021-11-10 | $8.76M 10-Q · filed 2020-11-10 | ||||||
| 2020-06-30 | $6.34M 10-Q · filed 2021-08-11 | |||||||
| 2020-03-31 | -$3.94M 10-Q · filed 2021-05-17 | |||||||
| 2019-12-31 | -$24.09M 10-K · filed 2021-03-11 | |||||||
| 2019-09-30 | -$19.22M 10-Q · filed 2020-11-10 | |||||||
| 2019-06-30 | -$14.46M 10-Q · filed 2020-08-12 | |||||||
| 2019-03-31 | -$9.19M 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $42.35M 10-K · filed 2020-03-16 | |||||||
| 2018-09-30 | $48.54M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |